Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Product information and disease descriptionProduct description

Phase of product development

18 evidence topics · 17 sources

Regulatory status: Submission planned; U.S. accelerated approval application planned if the AMPLITUDE interim analysis, with data expected in early 2027, is positive
Launch

No evidence found.

Authorisation status in the European Union: not authorised
FieldQuoted record
Investigational medicinal product“VX-147 film-coated tablet”
Active substance“Inaxaplin”
Authorisation status“Not authorised”
Medicine status in the EU“No EU-wide authorisation listed”
Interim analysis endpoints: company wording from March 2022 to September 2025
FDA orphan drug and Fast Track designations

No evidence found.